Epicardial ablation is a specialized medical procedure employed to treat certain cardiac arrhythmias by targeting abnormal electrical pathways on the outer surface of the heart, known as the epicardium. This technique is particularly useful when traditional endocardial ablation, which involves accessing the heart's inner chambers, proves inadequate. Cardiac arrhythmias, characterized by irregular heartbeats, can significantly impact an individual's quality of life and pose serious health risks. Epicardial ablation is often employed when arrhythmias originate in regions not easily reached through traditional methods. During the procedure, a catheter is carefully guided to the epicardium, and radiofrequency energy is applied to create controlled lesions, interrupting the faulty electrical signals causing the arrhythmia. This advanced intervention has shown promising results in managing complex arrhythmias, providing patients with an effective option for restoring normal heart rhythm and improving overall cardiovascular health. As with any medical procedure, thorough evaluation and consultation with a cardiac specialist are crucial to determine the most appropriate treatment plan for each patient.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India